Abstract: The presently-disclosed subject matter includes compounds including a cyclooxygenase enzyme inhibitor moiety and a moiety derived from a drug of interest. In some embodiments, the drug of interest is an opioid. In some embodiments, the compound includes a diclofenac moiety and a naltrexone or naltrexol moiety. The compounds allow for enhanced delivery rates across skin.

Abstract: A combination of: a first tetracycline (TC) component; and a second component capable of releasing nitric oxide (NO) or a nitrate capable of mimicking NO effects in vivo (NO mimetic). The combinations of the invention advantageously act as more effective MMP modulators with selective reductions in circulating MMP-9 levels in-vivo and inhibitory effects on MMP-2 and MMP-9 levels in-vitro. The combinations of the invention also advantageously act as modulators of inflammation mediators. The co-existence of abnormalities of MMP enzymes and inflammation in many diseases make these characteristics advantageous. Therefore, the various combinations of the invention find utility in medical applications where MMPs and/or inflammation is implicated.

Abstract: The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydromorphone (4,5-?-epoxy-3-hydroxy-17-methyl morphinan-6-one) to form novel prodrugs/compositions of hydromorphone. The hydromorphone prodrugs of the present technology have decreased side effects and decreased potential for abuse compared to unconjugated hydromorphone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.

Abstract: A dasatinib and nonlinear configuration polyethylene glycol conjugate represented by formula I, wherein core is the core structure of a nonlinear configuration of polyethylene glycol, selected from a residue of pentaerythritol, methylglucoside, sucrose, diethylene glycol, propanediol, glycerol or polyglycerol removaed the hydrogen atom from the hydroxyl group; P is a polyethylene glycol residue with a number-average molecular weight of 300-60000 Da; X is selected from single bond, —CH2CO—, —CH2CH2OCO— or CH2CH2NHCO—; and i is selected from 3, 4, 6 or 8.

Abstract: Provided are methods of producing mono- and di-pegylated IL-10.

Abstract: A complex includes RNA and a positively charged modified polysaccharide selected from starch, amylose, amylopectin, galactan, chitosan, or dextrin. The complex can be formed into a pharmaceutical composition. The complex can be used in methods for RNA transfection, gene therapy and treatment of a disease, disorder or condition. The positively charged modified polysaccharide can be used in connection with RNA transfection into cells.

Abstract: The present invention includes a method of modulating the phagocytic activity of at least one phagocyte in a subject. The present invention also includes a method of providing a composition resistant to phagocytosis to a subject. The present invention further includes a method of treating, ameliorating or preventing an inflammatory disease in a subject.

Abstract: The present invention relates to the use of alpha (2) macroglobulin complexes isolated from the serum of a mammal. The invention also relates to methods for making such complexes and compositions comprising alpha (2) macroglobulin complexes, isolated from the serum of a mammal, wherein such compositions are used in methods for the treatment and prevention of cancer and infectious disease. The invention also relates to methods for treating and preventing cancer and infectious disease using such complexes comprising, isolated from the serum of a mammal. The invention also encompasses methods for production of alpha (2) macroglobulin complexes.

Abstract: Peptide ligands for transporting therapeutic agents across the intestinal epithelial barrier that ordinarily are inadequately absorbed and must be delivered by alternative means, which contain an isolated amino acid sequence wherein at least one pair of amino acids are of an opposite charge and the pair members are separated by a spacer of 1-12 amino acid residues including at least one hydrophobic amino acid, and wherein the length of the amino acid sequence is greater than 5 and less than 20 amino acids. Pharmaceutical compositions for gastro-intestinal delivery and methods for the gastrointestinal delivery of poorly absorbed therapeutic agents are also disclosed.

Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.

Abstract: Acyclic CB[n]-type compounds, methods of making such compounds, and uses of the compounds. For example, these compounds can be used as nanocontainers to solubilize pharmaceutical agents. Also provided are compositions and methods of using them for therapy or prophylaxis of a wide variety of conditions for which therapy or prophylaxis is desirable.

Abstract: Disclosed herein are methods and compositions for inhibiting viral entry into cells.

Abstract: Embodiments of the present invention provide for the facile generation of a stable recombinant fusion polypeptides with intrinsic fluorescent properties. The recombinant antibodies may be suitable for qualitative and/or quantitative immunofluorescence analysis. Generally, the fluorescent polypeptides include a fluorescent domain comprising a C-terminus and an N-terminus; a first antibody domain covalently linked to the C-terminus; and a second antibody domain covalently linked to the N-terminus.

Abstract: A method of performing Nuclear Magnetic Resonance (NMR) spectroscopy or Magnetic Resonance Imaging (MRI). The methods may include: a) generating a compound comprising a first nuclear species (I1), a second nuclear species (I2), a third nuclear species (S), a heteronuclear coupling asymmetry (|J1S?J2S|) and a nuclear singlet state spin order localized on I1 and I2; b) transferring the nuclear singlet state spin order into heteronuclear magnetization localized on S by applying a single, non-recursive pulse sequence at a low magnetic field in the strong coupling regime of protons; and c) performing NMR spectroscopy or MRI with the compound comprising heteronuclear magnetization localized on S. The |J1S?J2S| may be non-zero. The pulse sequence may include a plurality of sequential radio frequency pulses separated by independent evolution interval.

Abstract: The present invention relates to bacteria-targeted contrast agents for magnetic resonance imaging (MRI). In particular, the present invention relates to bacteria targeted MRI contrast agents that can be used to detect bacteria in vivo or in vitro. In certain embodiments, the contrast agents comprise a metal chelate conjugated to at least two Zn-dipicolylamine groups.

Abstract: The present invention relates to a sterilizing device (1), comprising at least one chamber (2) for sterilizing products (4), a primary fluid circuit (3) connected to the chamber (2) for providing hot water and/or hot steam to the chamber, a secondary fluid circuit (8) for heating and/or cooling the primary fluid circuit (3), wherein the secondary fluid circuit (8) is connected to the primary fluid circuit (3) by means of a second heat exchanger (5), and a stratified storage tank (11) in the secondary fluid circuit (8) having a plurality of temperature zones (12), wherein the temperature zones (12) can be separately charged with and discharged of the fluid of the secondary fluid circuit (8).

Abstract: A method for a smart-device comprising receiving a user selection of an icon on a display, initiating acquisition of a first image of a target surface using a camera in response to receiving the selection, directing power to an UV-LED disposed proximate to the camera, wherein the power is provided to the UV-LEDs for less than about 0.5 seconds, while power is provided to the UV-LED, initiating acquisition of a second image of a target surface using the camera, determining an image visually highlighting a contaminant on the target surface in response to the first and second images, determining an object type associated with the target surface, in response to the first image, determining geographic data, and storing the image, the object type, and the geographic data in a memory.

Abstract: In an embodiment, a sterilization apparatus, adapted to sterilize a liquid to be sterilized, comprises a first sterilization light source, a first container and a sterilization container. The first sterilization light source includes a carrier, a plurality of LED packages and a plurality of collimating units, wherein the plurality of LED packages are disposed on and electrically connected to the plurality of carriers, and each of the plurality of collimating units separately is disposed on a corresponding LED package. The first container accommodates the first sterilization light source, and defines a first light-mixing space. The sterilization container includes an accommodating space for accommodating the liquid, wherein the first container is assembled together with the sterilization container, and the first light-mixing space is disposed between the first sterilization light source and the accommodating space.

Abstract: A method and device for destroying and inhibiting exposure to microbes and infection includes a first element and a second element, and a power source. At least one of the elements includes antimicrobial metal, which, when energized by the power source, produces ions that are lethal to microbes. The device can be incorporated into virtually any useful object. During normal use of the object, electrical communication is established between the two elements, causing current supplied from the power source to flow through the antimicrobial metal. The two elements are configured and arranged to ensure that ions flowing from the antimicrobial metal flow through the region in which it is desired to kill microbes. The antimicrobial metal can be on the surface of the element, incorporated into the material making up the element, or provided in any other way that allows the antimicrobial effect to be achieved.

Abstract: A Fenton reaction catalyst including a reaction product as an active component, in which the reaction product is obtained by using roasted and ground coffee beans (in particular, coffee grounds) or tea leaves (in particular, tea dregs) as feedstocks for supplying a component having a reduction effect, and mixing the feedstocks for supplying the component having a reduction effect with an iron-supplying source containing divalent or trivalent iron in the presence of water. The Fenton reaction catalyst can be used to generate hydroxy radicals from hydrogen peroxide. The Fenton reaction catalyst can maintain iron in a divalent state for a long period of time.

Abstract: A method for catalyzing a Fenton reaction, including adding hydrogen peroxide to a Fenton reaction catalyst, the Fenton reaction catalyst including a reaction product, wherein the reaction product is obtained by using roasted and ground coffee beans and/or tea leaves as a feedstock for supplying a component having a reduction effect, and mixing the feedstock for supplying the component having a reduction effect with an iron-supplying source containing divalent or trivalent iron in the presence of water.

Abstract: The invention includes an improved multiple component wax object that may be advantageously cubic or in another shape such as similar to tree bark that may be melted in a conventional warmer or candle melting device. Packaging for the cubic wax melts may be advantageously employed as a layered container for cooling as well as storing and transporting a group of wax melts. Packaging for the melts may also serve as discrete containers for several melts having different constituents.

Abstract: A composite material having inherent microbicidal activity is herewith described. The microbicidal composite material comprises of a first layer having a first predefined thickness and a first predefined stitch/thread density; a second layer having a second predefined thickness and a second predefined stitch/thread density; an intermediate layer having a third predefined thickness and a third predefined stitch/thread density, wherein the intermediate layer is sandwiched between the first layer and the second layer, and where the intermediate layer is connected to the first layer and the second layer to form a three dimensional structure, and where each layer in the three dimensional structure has a plurality of apertures. Further, at least one layer in the three dimensional structure comprises at least one of microfibers and nanofibers having augmented surface moieties, wherein the augmented surface moieties allow for binding of a microbicidal agent to impart the inherent microbicidal activity.

Abstract: The present invention provides a preparation comprising fibrinogen and a sulfated polysaccharide as a one component composition or as a kit of parts comprising fibrinogen and sulfated polysaccharide as separated components. The present invention further provides a fibrin clot like structure obtainable by a defined process, a hemostatic patch, a two-component syringe system and various uses of the described preparations, fibrin clot like structures and patches.

Abstract: This invention relates to methods and compositions for preparation of silk-PEGs based biomaterials through crosslinking by chemically reacting active polyethylene glycols (PEGs) possessing different chemical groups (e.g., thiols and maleimides functionalized PEGs) that are additionally stabilized by the beta-sheet formation of silk fibroin. The crosslinked silk-PEGs biomaterials present strong adhesive properties, which are comparable to or better than the current leading PEG-based sealant, depending on the silk concentration in the silk-PEGs biomaterials. In addition, the silk-PEGs based biomaterials are cytocompatible, show decreased swelling behavior and longer degradation times, which make them suitable for hemostatic applications where the current available tissue sealant products can be contraindicated.

Abstract: A system is provided, including a plurality of donor cells and a first alginate structure that encapsulates the plurality of donor cells. The first alginate structure has a guluronic acid concentration of between 64% and 74%. The system additionally includes a second alginate structure that surrounds the first alginate structure, the second alginate structure having a mannuronic acid concentration of between 52% and 60%. A selectively-permeable membrane is coupled at least in part to the second alginate structure. Other embodiments are also described.

Abstract: The present invention is directed to a magnesium alloy containing 5.0% by wt.-25.5% by wt. dysprosium, 0.01% by wt.-5.0% by wt. neodymium and/or europium, 0.1% by wt. 3.0% by wt. zinc, 0.1% by wt.-2.0% by wt. Zirconium, and balance to 100.0% by wt. magnesium, being degradable under physiological conditions and which is particularly suitable for the production of absorbable stents and to stents made thereof.

Abstract: The present disclosure relates to compositions useful in synthetic bone graft applications. Particularly, the disclosure teaches moldable bone graft compositions, methods of making said compositions, and methods of utilizing the same.

Abstract: A method for producing sterile, decellurized bioprosthetic tissue comprising: (a) contacting a human tissue with a hypotonic solution to produce a lysed tissue, (b) contacting the lysed tissue with a first surfactant to produce a surfactant-treated tissue, (c) contacting the surfactant-treated tissue with a nuclease enzyme solution to produce an enzyme-treated tissue, (d) contacting the enzyme-treated tissue with a cleaning solution comprising a second surfactant, a chaotropic agent or a mixture thereof to produce a decellurized tissue and (e) contacting the decellurized tissue with a bioburden reducing agent to produce the final bioprosthetic tissue. Kits to be used in conjunction with said method, as well as, the bioprosthetic tissue produced via said method are also provided.

Abstract: The present invention relates to a resorbable polymeric mesh implant, that is intended to be used in the reconstruction of soft tissue defects. The mesh implant comprises at least a first and a second material, wherein the second material is substantially degraded at a later point in time than the first material following the time of implantation. The mesh implant is adapted to have a predetermined modulus of elasticity that gradually is decreased until the mesh implant is completely degraded and subsequently resorbed. Due to the gradual decrease in the modulus of elasticity of the inventive mesh implant, the regenerating tissue may gradually take over the load applied to the tissue defect area.

Abstract: The disclosure provides biodegradable implantable devices such as a stent comprising a biodegradable polymeric wherein the polymeric material is treated to control crystallinity and/or Tg. The stent is capable to expand at body temperature in a body lumen from a crimped configuration to a deployed diameter and have sufficient strength to support a body lumen.

Abstract: A polymeric composition includes a polymer matrix having a lipophilic discrete nitric oxide adduct and/or a polymeric nitric oxide adduct associated therewith, by covalent attachment to the polymer matrix and/or by dispersion within the polymer matrix, with the discrete nitric oxide adduct and/or the polymeric nitric oxide adduct being capable of releasing nitric oxide (NO). The polymeric composition further includes an ester capped poly(lactide-co-glycolide) (PLGA) additive to at least one of increase, prolong, and control NO release rates from the lipophilic discrete nitric oxide adduct and/or the polymeric nitric oxide adduct.

Abstract: Drug-delivery systems such as drug-delivery stents having an anti-proliferative agent such as everolimus and an anti-flammatory agent such as clobetasol are provided. Also disclosed are methods of treating a vascular impairment such as restenosis or vulnerable plaque.

Abstract: A method of operating a counterpulsation device (CPD) in a human or animal subject is disclosed, the method including: receiving a heart beat signal indicative of the heart beat of the subject; providing counterpulsation therapy by controlling the pressure supplied to a CPD drive line in pneumatic communication with the CPD to cause the CPD to alternately fill with blood and eject blood with a timing that is determined at least in part based on the heart beat signal; while providing counterpulsation therapy, receiving a CPD drive line pressure signal indicative of the pressure in the CPD drive line; and adjusting the pressure supplied to the drive line based at least in part on the drive line pressure signal.

Abstract: A blood circulation assist system comprising an inflow cannula having a lumen and an insertion device configured to be received therein and to facilitate insertion of a portion of the inflow cannula into a heart chamber. The insertion device includes a shaft having distal and proximal end portions and a plurality of lumens. A first lumen is configured to receive a guidewire and a second lumen is configured to receive a pressurized fluid. A tip connected to the distal end portion of the shaft is configured for insertion into the heart chamber. The tip has a hollow interior communicating with the first shaft lumen. An inflatable member is coupled to the distal end portion of the shaft and includes a hollow interior in fluid communication with the second shaft lumen. The inflatable member is movable between deflated and inflated configurations for releasably securing the insertion device to the inflow cannula.

Abstract: The invention relates to an apparatus and a process for mass- and/or energy-transfer between two media, in particular between blood and a gas/gas mixture, having a chamber (1) through which a first medium, in particular blood, flows and in which a bundle of mass- and/or energy-permeable hollow fibers through which the second medium can flow and around which the first medium can flow is arranged transverse to the flow direction of the first medium, in which the chamber (1) is configured as an elastic shell (3) at least in a region which completely surrounds the bundle, where a rigid housing (6) is arranged around the elastic shell (3) and the inner wall of the housing contacts the shell (3) in a plurality of first regions (9) and the inner wall of the housing is not in contact with and is in particular at a spacing from the shell (3) in at least one second region (10), preferably a plurality of second regions (10) in the direction of the extension of the hollow fibers, where the one hollow space or at least on

Abstract: This disclosure relates to medical fluid sensors and related systems and methods. In certain aspects, a method includes reading an indicia of a medical fluid cartridge to determine a volume of a fluid passageway of the medical fluid cartridge indicated by the indicia, receiving radio frequency energy generated by excited atoms in medical fluid in the fluid passageway of the medical fluid cartridge, and determining a concentration of a substance in the medical fluid based on the determined volume of the fluid passageway of the medical fluid cartridge indicated by the indicia and the received radio frequency energy generated by the excited atoms in the medical fluid in the fluid passageway of the medical fluid cartridge.

Abstract: A method for the filling and flushing of a blood tube set including a pump segment for a blood pump, an arterial line connected to an inlet of a dialyser, a venous line connected to an outlet of a dialyser, a substituate line connected to a substitute port and having a pump segment for a substitute pump, and a three-way connector connected to the arterial line, the venous line and a rinse port. The method includes the steps of opening the rinse port, filling and simultaneously flushing the arterial and venous lines with the substituate supplied from the substitute line via the substitute pump, while substituate is drained off via the rinse port, closing the rinse port, and circulating the substituate in the circuit of arterial line, dialyser and venous line by the blood pump.

Abstract: The invention is directed to providing, at the exit from the nozzle of an irrigator, an intermittent gas-liquid jet for enabling effective cleaning, while being easy to use, A bulb (1) has an aerator introduced therein which is in the form of a tubular element (7) with open tips (71, 72) and a perforation region (73) in the side wall of the element (7), the region having at least one hole. The end of the tubular element (7) on the open-ended side is freely disposed in the cavity of the bulb (1), and the tip (71) is disposed with clearance from the base of the bulb.

Abstract: A description of a bottle container assembly for use by patients for daily handling of glass insulin ampules and/or a variety of prescription medications and small medicine bottles. The container assembly is designed for frequent daily use at home, work or travel. It is constructed to address the safe handling, use and safe storage of medicines and in particular the storage of a variety of glass ampules containing insulin or other hypodermic solutions. The invention provides a safe, suitable and reusable container assembly to hold various insulin ampules replacing the fragile cardboard boxes they are shipped in by the manufacturers.

Abstract: A disposable fluid connector includes a first single-use tubing component having proximal and distal ends and a second single-use tubing component having proximal and distal ends, where the first single-use tubing component and the second single-use tubing component are each usable only for a single patient procedure. The disposable fluid connector also includes a connection comprising an electrical connector that is configured to electrically connect the connection to both a powered injector and to an external medical device, where the disposable fluid connector comprises a disposable cassette including a portion that is non-removably attached to both the first single-use tubing component and the second single-use tubing component.

Abstract: A bottle support for an injection or infusion device with a main body, which has at least one bottle holder for the holding of a neck of a supply bottle. In order to bring about as simple and quick an equipping as possible of the injection device with supply bottles with different sizes and to hold the supply bottles securely in the bottle support, provision is made so that a shaft is formed in the main body, in which a tension slide, pretensioned with a spring, is supported so it can be displaced linearly. In a first position, the tension slide locks the neck of the supply bottle, and in a second position, the neck of the supply bottle is released.

Abstract: Disclosed are methods, systems, devices and articles, including method for adaptive wireless communication transmissions between units of an ambulatory portable medical device. The method includes obtaining data relating to wireless transmissions between the units of the medical device, and setting one or more attributes of wireless transmission of one or more messages between the units of the medical device based, at least in part, on the obtained data.

Abstract: The invention relates to an insertion device comprising—a penetrating member (50) connected to transformation means (52), —a moving part (38) comprising guiding means (39) which guiding means (39) restrict the movement of the transformation means (52) and guide the penetrating member (50) from a first to a second position in a first direction, i.e. the direction of insertion, towards the injection site, and—a stationary housing (30) comprising guiding means (32) which guiding means (32) restrict the movement of the moving part (38). The guiding means (32) guide the moving part (38) in a second direction which is linear and different from the first direction i.e. the direction of insertion.

Abstract: An apparatus for delivery of fluids to a patient includes an inlet tube and an outlet tube connected to each other at an angular joint. A rotary valve and a piston are fitted to the angular joint forming a chamber. The rotary valve is provided with a priming channel notch and a pumping notch. For priming operation with the fluid delivery apparatus, a user sets the rotary valve to a priming position. During pumping operation, the rotary valve rotates in coordination with the piston to transfer a quantum of fluid from the inlet tube to the outlet tube via the chamber. A second piston is optionally provided on the outlet tube for smoothing out flow rate pulsations.

Abstract: An automatic applicator for liquid pharmaceutical preparations, particularly for multiple injection application of set doses of a medicine from an exchangeable container is provided. The automatic applicator includes a body housing connected to a housing of an exchangeable container with a medicine having a plunger, the said plunger being displaced only linearly by an integrated driving unit, suitable for immobilizing, driving, leading linearly and blocking rotation of the plunger, driven via a double action clutch, by a tensioning spring situated in the body housing, the spring tensioned by a rotary hand-dose-setting ring via the double action clutch, wherein the driving unit is activated by a trigger unit and a dose is indicated by an indicating arrangement. The automatic applicator further includes at least one block key placed in an upper part of a ratchet barrel, collaborating with at least one key placed in an internal part of the body housing.

Abstract: The invention relates to a syringe having a longitudinal axis and comprising a barrel assembly including a barrel extending longitudinally between a proximal end and a distal end, and a collar provided at the proximal end of the barrel and defining a reading window. The syringe also comprises a plunger including a longitudinally extending graduation portion that is at least partially longitudinally slidably received in the barrel, and that provides for at least two mutually different visually readable graduations, wherein respective graduations extend along the longitudinal axis and are alternatively selectable by rotation of the graduation portion around the longitudinal axis, such that a selected graduation is visible through the reading window when the plunger is slid into and out of the barrel during use.

Abstract: A syringe measurement marking system for use with a syringe that includes a barrel and a plunger is marked with patient-based numerical measuring indicia on the plunger. The patient-based numerical measuring indicia is non-volumetric in nature and instead indicates patient dosing criteria such as weight, age, height, blood sugar level, or any other patient criteria by which dosing is determined. The plunger may contain more than one set of patient-based numerical measuring indicia, such as one set for adults or one set for pediatrics, or one set for a first dose of a medication and one set for a second dose, or one set based on weight in pounds and one set based on weight in kilograms. The syringe barrel will contain one or more measurement lines.

Abstract: The invention describes a locking arrangement which is advantageously used in an injection device for administering a medicinal drug, such as insulin for example.

Abstract: A medication delivery device comprises a housing (1), a cap (2) configured to be attached to the housing (1) and a locking means (16, 17) configured to lock the cap (2). In a first state the cap (2) is detachable and in a second state the locking means (16, 17) locks the cap (2) if the cap (2) is attached.